AU:OCC Stock Latest News
Company AnnouncementsOrthocell outlines terms and limitations of Q1 FY27 investor webinar1w agoOCC
Company AnnouncementsOrthocell boosts Remplir-driven revenue as U.S. rollout and Asian expansion gain pace1w agoOCC- Company AnnouncementsOrthocell’s Remplir shows strong outcomes in complex prostate cancer surgeries2w agoOCC
Company AnnouncementsOrthocell Sets November Date for Hybrid 2026 AGM and Moves to Digital Meeting Materials1M agoOCC
Company AnnouncementsOrthocell Seeks Deloitte as Auditor to Support Global Growth1M agoOCC
Company AnnouncementsOrthocell Makes First Remplir Sales in Thai Nerve Repair Market1M agoOCCCompany AnnouncementsOrthocell issues new shares after option exercise, boosting tradable stock1M agoOCC
Company AnnouncementsOrthocell Files 2026 Corporate Governance Appendix with ASX2M agoOCC
Company AnnouncementsOrthocell posts full-year 2026 results and details progress in regenerative medicine portfolio2M agoOCC
Company AnnouncementsOrthocell to Showcase Regenerative Growth Strategy at Canaccord Conference2M agoOCC
Company AnnouncementsOrthocell Targets Global Investors at Canaccord Growth Conference2M agoOCC
Company AnnouncementsOrthocell Relocates Registered Office to Murdoch University Campus3M agoOCC
Company AnnouncementsOrthocell hits record revenue as Remplir adoption accelerates and global rollout advances3M agoOCC
- Company AnnouncementsOrthocell to Unveil Quarterly Results and Detail U.S. Rollout of Remplir3M agoOCC
Company AnnouncementsOrthocell Expands Humanitarian Use of Remplir Nerve Repair Device in Ukraine4M agoOCC- Company AnnouncementsOrthocell issues new shares after employee option exercise under equity incentive plan6M agoOCC
- Company AnnouncementsOrthocell Seeks ASX Quotation for 445,696 New Shares6M agoOCC
Company AnnouncementsOrthocell logs first Remplir sales in Canada, advancing global nerve repair rollout6M agoOCCCompany AnnouncementsOrthocell’s Remplir Nerve Repair Device Posts Near-90% Success in Real-World Study6M agoOCC
Company AnnouncementsOrthocell Flags Risks and Confidentiality in Q3 FY26 Investor Briefing6M agoOCC
